Full Press Release Details
IDEAYA Announces IDMC Recommendation of Move Forward Dose in Part 2a of Registration Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA A2 Negative Metastatic Uveal Melanoma.
IDYA
IDEAYA Announces IDMC Recommendation of Move Forward Dose in Part 2a of Registration Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA A2 Negative Metastatic Uveal Melanoma
Key Takeaway: IDEAYA Announces IDMC Recommendation of Move Forward Dose in Part 2a of Registration Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA A2 Negative Metastatic Uveal Melanoma
Price reaction · baseline $26.05 (2024-12-16 close) · hit after-hours · clean, no other IDYA news in the window
day 0 close · peak
+1.1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma